Download the TumorGraft3D Platform sheet to learn more about Champions' 3D ex vivo platform, assay features and applications, model characterization, and available endpoints.
In the study presented in this poster, we employed our TumorGraft3D platform to test osimertinib in 2 NSCLC models, one EGFR-mut and one EGFR-wt, and vemurafenib in 2 BRAF-mut melanoma models. Then we used the Lumin Pharmacology Analysis tool to evaluate the efficacy and synergistic effect of combining osimertinib and cisplatin in the EGFR-wt NSCLC TumorGraft3D model.
Watch Champions' Senior Global Scientific Director, Stefano Cairo, talk about the importance of next-gen multi-omic characterization to select the most relevant models for your preclinical studies, improving accuracy in overall study results.
Traditionally, 3D tissue culture models have been cultured using a matrix-based approach, where the supportive extracellular matrix is derived from natural or synthetic sources, however, the use of matrices can also pose several challenges. Novel matrix-free approaches instead allow for the self-organization of 3D tissue culture models without the use of an exogenous matrix, overcoming many of the challenges linked to matrix use.
